# Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

Study · id `cardio:ct-nct03862716` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03862716](<https://clinicaltrials.gov/study/NCT03862716>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03862716

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

## Technical summary

Registry record NCT03862716. Randomized; no masking; primary purpose treatment. Start 2019-04-23 (actual); primary completion 2022-06-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 159 participants (enrolled count; ClinicalTrials.gov record NCT03862716, source copy `cardio:ctgov-nct03862716-2023-10-25`, retrieved 2026-10-26)
- Started: 2019-04-23 (actual) (ClinicalTrials.gov record NCT03862716, source copy `cardio:ctgov-nct03862716-2023-10-25`, retrieved 2026-10-26)
- Primary completion: 2022-06-15 (actual) (ClinicalTrials.gov record NCT03862716, source copy `cardio:ctgov-nct03862716-2023-10-25`, retrieved 2026-10-26)
- Completion: 2023-07-31 (actual) (ClinicalTrials.gov record NCT03862716, source copy `cardio:ctgov-nct03862716-2023-10-25`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT03862716, source copy `cardio:ctgov-nct03862716-2023-10-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03862716-2023-10-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
- Acronym: REMITiDegLira
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): IDegLira
- Intervention (Drug): insulin degludec
- Intervention (Drug): Metformin
- Intervention (Behavioral): Lifestyle Therapy
- Lead sponsor: Population Health Research Institute
- Lead sponsor class: OTHER
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Population Health Research Institute (`cardio:org-population-health-research-institute`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 7ad0d2822a2c69375db7242ca13ab1a3a8ec95e6cb6a631d40f081027de323e3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
